NEW YORK (GenomeWeb) – Genomic Health and Biocartis announced today that they have entered into an exclusive agreement under which they will develop an in vitro diagnostic version of Genomic Health's Oncotype DX breast cancer test on Biocartis' Idylla platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.